A leader in allergen immunotherapy (AIT), Stallergenes Greer has been present in the United States since 1904.

Headquartered in Baar, Switzerland, with locations in Lenoir, North Carolina and San Diego, California, Stallergenes Greer’s business in the United States is part of a leading global biopharmaceutical company specialising in the development and commercialisation of allergy immunotherapy (AIT) products and services for use in the diagnosis and treatment of allergies.

In the United States, we provide a broad range of allergen immunotherapy and diagnostic solutions for both human and veterinary use that make Stallergenes Greer an essential player in the American market.

Every day, our employees are committed to fulfilling our purpose: enabling precision medicine to improve life for people with allergies.

Allergen immunotherapy (AIT) is an allergy treatment designed to treat the underlying cause of the disease as well as have a carry-over effect on all symptoms. After an accurate diagnosis of the type of allergy and responsible allergens, patients, in line with their healthcare professional’s prescription, receive a targeted treatment. Through the repeated administration of specific allergens, the immune system builds resistance¹ thus reducing symptoms when patients are exposed to the allergen in their environment.

¹ Global Atlas of Allergy, EAACI 2014